文献リスト

1) Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006; 41: 17-27

2) McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1485-92

3) Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352: 1426-32

4) Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1493-9

5) 飯野四郎, 松嶋 喬, 熊田博光, 他. Genotype1bか高ウイルス量のC型慢性肝炎に対するインターフェロンα-2bとSCH18908(リバビリン)の併用投与とインターフェロンα-2b単独投与との比較─二重盲検比較法を用いた用法・用量の検討─. 臨床医薬. 2002; 18: 565-91

6) Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958-65

7) Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-82

8) Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346-55

9) Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004; 40: 993-9

10) 飯野四郎, 沖田 極, 小俣政男, 他. Genotype1かつ高ウイルス量のC型慢性肝炎に対するPEG-インターフェロンα-2bとリバビリン48週併用療法の有用性─インターフェロンα-2bとリバビリン6カ月併用療法とのretrospectiveな比較─. 肝胆膵. 2004; 49: 1099-121

11) 熊田博光, 豊田成司, 後藤賢一郎, 他. Genotype 1かつ低ウイルス量, あるいはgenotype 2のC型肝炎に対するPEG-インターフェロンα-2bとリバビリン24週併用療法の有効性─インターフェロンα-2bとリバビリン24週間併用療法との比較─. 肝胆膵. 2006; 52: 645-63

12) 平松直樹, 小瀬嗣子, 林 紀夫. C型肝炎に対するPEG-IFN/リバビリン併用療法の進歩 ウイルス遺伝子型の違いによる治療法の実際 Genotype1型かつ高ウイルス量症例—臨床薬理試験から─. 肝胆膵. 2006; 53(増刊号): 9-14

13) Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006; 130: 1086-97

14) Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006; 131: 451-60

15) Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 2007; 132: 1270-8

16) Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006; 131: 997-1002

17) Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor Telaprevir. Gastroenterology. 2007; 132: 1767-77

18) Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007; 46: 631-9

19) Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007; 132: 103-12

20) Meyer-Wyss B, Rich Pegger H, et al. Comparison of two PEG-interferon alpha-2b doses (1. 0 or 1. 5μg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat. 2006; 13: 457-65

21) Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006; 131: 1040-8

22) Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005; 128: 636-41

23) D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005; 100: 1509-15

24) Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007; 46: 403-10

25) Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43: 954-60

26) Moucari R, Ripault MP, Oules V, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol. 2007; 46: 596-604

27) Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004; 40: 1260-5

28) Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352: 2609-17

29) von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129: 522-7

30) Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004; 126: 1302-11

31) Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004; 40: 1450-8

32) Hiramatsu N, Kurashige N, Oze T, et al. Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatl Res. 2007. in press

33) Oze T, Hiramatsu N, Kurashige N, et al. Early decline of hemoglobin correlates with prog-ression of ribavirin-induced hemolytic anemia during IFN plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol. 2006; 41: 862-72

34) Hiramatsu N, Oze T, Tsuda N, et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy？ Hepatol Res. 2006; 35: 185-9

35) Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology. 2006; 43: 54-63

36) Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat. 2006; 13: 762-9

37) Abergel A, Hezode C, Leroy V, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat. 2006; 13: 811-20

38) Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39: 1147-71

39) Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006; 130: 225-30

40) McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123: 1061-9

41) Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol. 2005; 43: 243-9

42) Berg C, Goncales FL Jr, Bernstein DE, et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat. 2006; 13: 435-40

43) Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. 2006; 130: 1098-106

44) Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004; 127: 1724-32

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp